Key facts
- This page summarizes Erin Quirk's Form 4 filing for Terns Pharmaceuticals, Inc. (TERN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Jan 2024, 19:17.
Erin Quirk - 23 Jan 2024 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)
- Reporting relationship
- President, Head of R&D
- Issuer ticker
- TERN
- Reported as of
- 23 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jan 2024, 19:17:02 UTC
- Prior SEC filing
- 03 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bryan Yoon, as Attorney-in-Fact for Erin Quirk
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Erin Quirk filed Form 4 for Terns Pharmaceuticals, Inc. (TERN) on 25 Jan 2024.
Change
- Previous filing in this sequence was filed on 03 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TERN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 23 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TERN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- Price
- $0.000000
- Shares after
- 150,000
- Date
- 23 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $5.46
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
Footnote F2
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.